The Solid Tumor Fusion Gene Panel is designed for identification of somatic known and novel gene fusions (or rarely pathogenic alternative transcripts due to gene rearrangements) in cancer patients. The test involves 157 clinical genes, which include kinases, transcriptional factors and others found to be recurrently altered in a variety of solid tumors. This panel evaluates regions of interest within 157 clinical genes for the potential rearrangements. Solid Tumor Fusion Gene Panel includes:
ACVR2A
CAMTA1
ESR1
FOSB
KMT2A
MUSK
NTRK2
PIK3CA
RAD51B
TFE3
AKT1
CCNB3
ESRRA
FOXO1
MALT1
MYB
NTRK3
PKN1
RAF1
TFEB
AKT2
CCND1
ETV1
FOXO4
MAML2
MYBL1
NUMBL
PLAG1
RELA
TFG
AKT3
CIC
ETV4
FRK
MAP2K1
MYC
NUTM1
PPARG
RET
TGFA
ALK
CLDN18
ETV5
FUS
MAST1
NAB2
NUTM2A
PRB3
RLF
THADA
AR
CSF1
ETV6
GLI1
MAST2
NCOA1
NUTM2B
PRDM10
ROS1
TMPRSS2
ARAF
CSF1R
EWSR1
GLIS2
MBTD1
NCOA2
PAX3
PRKACA
RSPO2
TTYH1
ARHGAP26
DEK
FGF1
GRB7
MDM2
NCOA3
PAX5
PRKACB
RSPO3
USP6
ATXN1
DNAJB1
FGFR1
GRM1
MEAF6
NFATC2
PAX7
PRKCA
SRF
VGLL2
AXL
EGF
FGFR2
HMGA2
MERTK
NFE2L2
PAX8
PRKCB
SS18
VGLL3
BCOR
EGFR
FGFR3
IGF1R
MET
NFIB
PDGFB
PRKCD
SS18L1
WWTR1
BCORL1
EPC1
FGFR4
INSR
MGEA5
NOTCH1
PDGFD
PRKD1
STAT6
YAP1
BIRC3
ERBB2
FGR
JAK2
MKL2
NOTCH2
PDGFRA
PRKD2
TAF15
YWHAE
BRAF
ERBB3
FLT1
JAK3
MN1
NR4A3
PDGFRB
PRKD3
TCF12
BRD3
ERBB4
FLT3
JAZF1
MSH2
NRG1
PGR
PTCH1
TEK
BRD4
ERG
FOS
KIT
MSMB
NTRK1
PHF1
PTPN1
TERT
Performing Laboratory / Facility
UCLA Molecular Diagnostics Laboratories (MDL)
Performing Section
Molecular Pathology
Availability
Monday through Friday, 0700-1700
Turnaround Time
14 days from receipt of required specimen in performing lab
Methodology
The Solid Tumor Fusion
Panel uses Archer's
AMP™ technology to
interrogate specific regions
of genes. This assay
features a highly optimized
oligonucleotide probe pool
with specificity for the
recurrent break points in
the fusion partner genes
that are recurrently
rearranged in a variety of
solid tumors. This panel
evaluates regions of
interest within 157 clinical
genes for the potential
rearrangements.
Sequencing of fusion
libraries is performed on
Illumina Miseq.
Use
The Solid Tumor Fusion
Panel evaluates the gene
fusion in cancer patients.
The test involves 157
clinical genes, which
include kinases,
transcriptional factors and
others found to be
recurrently altered in a
variety of solid tumors.
The findings of this assay
act in conjunction with
clinical history and
pathologic diagnoses for
the clinical management of
patients with different solid
tumor malignancies.
Limitations
The panel should not be used for detecting residual fusions. This test cannot detect gene fusions outside the regions of interest (ROI) defined by the test. This assay is at risk of false negatives when tumor purity is low and/or RNA quality is suboptimal. Some fusions may not be detected due to local sequence characteristics or the presence of pseudogene.
Specimen Type
10 unstained formalin-fixed paraffin-embedded (FFPE) slides with ≥20% of neoplastic cells on the entire slide or in the circled tumor area. An H&E from the same tumor block is required.
Shipping and Handling Instructions
Transport specimen at room temperature.
Causes for Rejection
Incorrect tissue type, damaged slides, tissue quantity not sufficient
Test Information
Test Name
Solid Tumor Fusion Gene Panel
Test Number
LAB9064
CPT Codes
81456
Test Includes
The Solid Tumor Fusion Gene Panel is designed for identification of somatic known and novel gene fusions (or rarely pathogenic alternative transcripts due to gene rearrangements) in cancer patients. The test involves 157 clinical genes, which include kinases, transcriptional factors and others found to be recurrently altered in a variety of solid tumors. This panel evaluates regions of interest within 157 clinical genes for the potential rearrangements. Solid Tumor Fusion Gene Panel includes:
ACVR2A
CAMTA1
ESR1
FOSB
KMT2A
MUSK
NTRK2
PIK3CA
RAD51B
TFE3
AKT1
CCNB3
ESRRA
FOXO1
MALT1
MYB
NTRK3
PKN1
RAF1
TFEB
AKT2
CCND1
ETV1
FOXO4
MAML2
MYBL1
NUMBL
PLAG1
RELA
TFG
AKT3
CIC
ETV4
FRK
MAP2K1
MYC
NUTM1
PPARG
RET
TGFA
ALK
CLDN18
ETV5
FUS
MAST1
NAB2
NUTM2A
PRB3
RLF
THADA
AR
CSF1
ETV6
GLI1
MAST2
NCOA1
NUTM2B
PRDM10
ROS1
TMPRSS2
ARAF
CSF1R
EWSR1
GLIS2
MBTD1
NCOA2
PAX3
PRKACA
RSPO2
TTYH1
ARHGAP26
DEK
FGF1
GRB7
MDM2
NCOA3
PAX5
PRKACB
RSPO3
USP6
ATXN1
DNAJB1
FGFR1
GRM1
MEAF6
NFATC2
PAX7
PRKCA
SRF
VGLL2
AXL
EGF
FGFR2
HMGA2
MERTK
NFE2L2
PAX8
PRKCB
SS18
VGLL3
BCOR
EGFR
FGFR3
IGF1R
MET
NFIB
PDGFB
PRKCD
SS18L1
WWTR1
BCORL1
EPC1
FGFR4
INSR
MGEA5
NOTCH1
PDGFD
PRKD1
STAT6
YAP1
BIRC3
ERBB2
FGR
JAK2
MKL2
NOTCH2
PDGFRA
PRKD2
TAF15
YWHAE
BRAF
ERBB3
FLT1
JAK3
MN1
NR4A3
PDGFRB
PRKD3
TCF12
BRD3
ERBB4
FLT3
JAZF1
MSH2
NRG1
PGR
PTCH1
TEK
BRD4
ERG
FOS
KIT
MSMB
NTRK1
PHF1
PTPN1
TERT
Performing Laboratory / Facility
UCLA Molecular Diagnostics Laboratories (MDL)
Performing Section
Molecular Pathology
Availability
Monday through Friday, 0700-1700
Turnaround Time
14 days from receipt of required specimen in performing lab
Methodology
The Solid Tumor Fusion
Panel uses Archer's
AMP™ technology to
interrogate specific regions
of genes. This assay
features a highly optimized
oligonucleotide probe pool
with specificity for the
recurrent break points in
the fusion partner genes
that are recurrently
rearranged in a variety of
solid tumors. This panel
evaluates regions of
interest within 157 clinical
genes for the potential
rearrangements.
Sequencing of fusion
libraries is performed on
Illumina Miseq.
Use
The Solid Tumor Fusion
Panel evaluates the gene
fusion in cancer patients.
The test involves 157
clinical genes, which
include kinases,
transcriptional factors and
others found to be
recurrently altered in a
variety of solid tumors.
The findings of this assay
act in conjunction with
clinical history and
pathologic diagnoses for
the clinical management of
patients with different solid
tumor malignancies.
Limitations
The panel should not be used for detecting residual fusions. This test cannot detect gene fusions outside the regions of interest (ROI) defined by the test. This assay is at risk of false negatives when tumor purity is low and/or RNA quality is suboptimal. Some fusions may not be detected due to local sequence characteristics or the presence of pseudogene.
Specimen Collection and Handling
Specimen Type
10 unstained formalin-fixed paraffin-embedded (FFPE) slides with ≥20% of neoplastic cells on the entire slide or in the circled tumor area. An H&E from the same tumor block is required.
Shipping and Handling Instructions
Transport specimen at room temperature.
Causes for Rejection
Incorrect tissue type, damaged slides, tissue quantity not sufficient
